AMG 986

Drug Profile

AMG 986

Alternative Names: AMG986

Latest Information Update: 09 Nov 2016

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Amgen
  • Class Heart failure therapies
  • Mechanism of Action G protein-coupled receptor agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Phase I Heart failure

Most Recent Events

  • 27 Oct 2017 Amgen plans a phase I trial for Heart failure (In volunteers, In patients with severely impaired renal function) in USA (PO) in November 2017 (NCT03318809)
  • 06 Oct 2016 Phase-I clinical trials in Heart failure in USA (unspecified route) (Amgen pipeline, October 2016)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top